Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by inthnoon Dec 04, 2001 2:49pm
1784 Views
Post# 4481668

RE: animal trial

RE: animal trialToday's news as I understand it is not related to what pfizer is doing with their animal trials.It is not known yet as to whether pfizer will actually be releasing any results soon,but my understanding is that they are still spending lots of money in this regards. Onc has stated that they want to procede with trials involving systemic administration. Phase 1 trials dealt with direct tumor injection which is basically what they would then be limited to for the phase 2 with the prostate. This is probabally one reason they are treating patients with early stage prostate cancer that hasn't metastiszed yet,but I believe that later trials will involve both direct tumor injection in association with systemic administration. As for the glio,pre-clinical and phase 1 in the animal studies shows that the reo-virus appears to spread past the original tumor and treat any spread or metastisis. Inthno
Bullboard Posts